Hepatic parenchymal enhancement at Gd-EOB-DTPA-enhanced MR imaging: Correlation with morphological grading of severity in cirrhosis and chronic hepatitis

Magnetic Resonance Imaging

Volumn 30, Issue 3, 2012, Pages 356-360

  Kanki, Akihiko ^a   Tamada, Tsutomu ^a   Higaki, Atsushi ^a   Noda, Yasufumi ^a   Tanimoto, Daigo ^a   Sato, Tomohiro ^a   Higashi, Hiroki ^a   Ito, Katsuyoshi ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Chronic hepatitis; Cirrhosis; Gd EOB DTPA; Magnetic resonance imaging; Morphologic changes

Indexed keywords

GADOXETIC ACID;

ADULT; AGED; ARTICLE; CELL FUNCTION; CHRONIC HEPATITIS; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG LIVER LEVEL; FEMALE; HUMAN; HUMAN CELL; LIVER CELL; LIVER CIRRHOSIS; LIVER PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; RETROSPECTIVE STUDY; SIGNAL INTENSITY MEASUREMENT;

AGED; AGED, 80 AND OVER; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HEPATITIS, CHRONIC; HUMANS; IMAGE ENHANCEMENT; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84857123822     PISSN: 0730725X     EISSN: 18735894     Source Type: Journal    
DOI: 10.1016/j.mri.2011.11.002     Document Type: Article

References (20)

1. Ito K., Mitchell D.G. Imaging diagnosis of cirrhosis and chronic hepatitis. Intervirology 2004, 47:134-143.
2. Narita M., Hatano E., Arizono S., Miyagawa-Hayashino A., Isoda H., Kitamura K., et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 2009, 44(7):793-798.
3. Tsuboyama T., Onishi H., Kim T., Akita H., Hori M., Tatsumi M., Nakamoto A., Nagano H., Matsuura N., Wakasa K., Tomoda K. Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging - correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 2010, 255(3):824-833.
4. Hamm B., Staks T., Muhler A., Bollow M., Taupitz M., Frenzel T., et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995, 195:785-792.
5. Vogl T.J., Kummel S., Hammerstingl R., Schellenbeck M., Schumacher G., Balzer T., et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996, 200:59-67.
6. Kim Y.K., Kim C.S., Han Y.M., Park G. Detection of small hepatocellular carcinoma: can gadoxetic acid-enhanced magnetic resonance imaging replace combining gadopentetate dimeglumine-enhanced and superparamagnetic iron oxide-enhanced magnetic resonance imaging. Invest Radiol 2010, 45:740-746.
7. Tsuda N., Matsui O. Cirrhotic rat liver: reference to transporter activity and morphologic changes in bile canaliculi - gadoxetic acid-enhanced MR imaging. Radiology 2010, 256(3):767-773.
8. Ichikawa T., Saito K., Yoshioka N., et al. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol 2010, 45(3):133-141.
9. Tanimoto A., Lee J.M., Murakami T., Huppertz A., Kudo M., Grazioli L. Consensus report of the 2nd international forum for liver MRI. Eur Radiol 2009, 19(suppl 5):S975-S989.
10. Tschirch F.T., Struwe A., Petrowsky H., Kakales I., Marincek B., Weishaupt D. Contrast-enhanced MR cholangiography with Gd-EOB-DTPA in patients with liver cirrhosis: visualization of the biliary ducts in comparison with patients with normal liver parenchyma. Eur Radiol 2008, 18:1577-1586.
11. Ryeom H.K., Kim S.H., Kim J.Y., et al. Quantitative evaluation of liver function with MRI Using Gd-EOB-DTPA. Korean J Radiol 2004, 5:231-239.
12. Utaroh M., Tomoaki I., Hironobu S., et al. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement?. J Magn Reson Imaging 2009, 30:1042-1046.
13. Planchamp C., Montet X., Frossard J.L., et al. Magnetic resonance imaging with hepatospecific contrast agents in cirrhotic rat livers. Invest Radiol 2005, 40:187-194.
14. Tamada T., Ito K., Sone T., Kanki A., Sato T., Higashi H. Gd-EOB-DTPA enhanced MR imaging: evaluation of biliary and renal excretion in normal and cirrhotic livers. Eur J Radiol 2010.
15. Kim T., Murakami T., Hasuike Y., et al. Experimental hepatic dysfunction: evaluation by MRI with Gd-EOB-DTPA. J Magn Reson Imaging 1997, 7:683-688.
16. Geier A., Dietrich C.G., Voigt S., et al. Effects of proinflammatory cytokines on rat organic anion transporters during toxic liver injury and cholestasis. Hepatology 2003, 38:345-354.
17. Geier A., Kim S.K., Gerloff T., et al. Hepatobiliary organic anion transporters are differentially regulated in acute toxic liver injury induced by carbon tetrachloride. J Hepatol 2002, 37:198-205.
18. Kitao A., Zen Y., Matsui O., Gabata T., Kobayashi S., Koda W., Kozaka K., Yoneda N., Yamashita T., Kaneko S., Nakanuma Y. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR imaging - correlation with molecular transporters and histopathologic features. Radiology 2010, 256(3):817-826.
19. Ito K., Mitchell D.G., Hann H.W., Outwater E.K., Kim Y. Compensated cirrhosis due to viral hepatitis: using MR imaging to predict clinical progression. AJR Am J Roentgenol 1997, 169(3):801-805.
20. Weinmann H.J., Schuhmann-Giampieri G., Schmitt-Willich H., Vogler H., Frenzel T., Gries H. A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Reson Med 1991, 22:233-237.